Video

Dr. Crawford on LHRH Agonists and GNRH Antagonists

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist as treatments for men with prostate cancer.

LHRH agonists are a compound which, when injected, a patient's testosterone increases before decreasing because it agonizes the receptor and creates an opposite effect, Crawford explains. LHRH agonists desensitize the receptors over time.

However, an antagonist is ideal, Crawford adds, because it simply shuts down the LH and FSH hormones. There are approximately 10 to 15 advantages for an antagonist over an agonist, he says. However, a disadvantage is an antagonist requires monthly dosing. Other side effects associated with antagonists include renal and cardiovascular failure and alkaline phosphatase reduction.

Crawford says further data is needed to determine whether GNRH antagonists demonstrate better outcomes in patients.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center